Literature DB >> 14502661

Use of functional imaging in Parkinsonism and dementia.

David J Burn1, John T O'Brien.   

Abstract

Neuropsychiatric symptoms, including dementia, frequently coexist with parkinsonian disorders and may cause diagnostic confusion as well as management problems. Functional imaging studies include single photon emission computerised tomography (SPECT), positron emission tomography (PET), proton magnetic resonance spectroscopy, diffusion tensor imaging, and functional magnetic resonance imaging. This review addresses the utility of these techniques, from the clinician's perspective, focusing on the most common causes of parkinsonism and cognitive impairment, Parkinson's disease with dementia, dementia with Lewy bodies, and Alzheimer's disease. The potential and limitations of these techniques for accurate and early diagnosis, monitoring disease progression, and establishing the pathophysiological basis underlying key clinical features are considered. The development of new probes for SPECT and PET cameras capable of labeling protein aggregates (e.g., beta-amyloid) will offer exciting new insights into the spatial and temporal pattern of pathophysiological processes. Longitudinal studies with clinicopathological correlation represent the "gold standard" for fully evaluating functional imaging techniques. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Year:  2003        PMID: 14502661     DOI: 10.1002/mds.10568

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  Measurement of gray and white matter atrophy in dementia with Lewy bodies using diffeomorphic anatomic registration through exponentiated lie algebra: A comparison with conventional voxel-based morphometry.

Authors:  R Takahashi; K Ishii; N Miyamoto; T Yoshikawa; K Shimada; S Ohkawa; T Kakigi; K Yokoyama
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-15       Impact factor: 3.825

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

3.  Rational design of amyloid binding agents based on the molecular rotor motif.

Authors:  Jeyanthy Sutharsan; Marianna Dakanali; Christina C Capule; Mark A Haidekker; Jerry Yang; Emmanuel A Theodorakis
Journal:  ChemMedChem       Date:  2010-01       Impact factor: 3.466

4.  Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease.

Authors:  Daniel Weintraub; Nicole Dietz; John E Duda; David A Wolk; Jimit Doshi; Sharon X Xie; Christos Davatzikos; Christopher M Clark; Andrew Siderowf
Journal:  Brain       Date:  2011-11-21       Impact factor: 13.501

5.  Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging.

Authors:  Wang Zhan; Gail A Kang; Graham A Glass; Yu Zhang; Cheryl Shirley; Rachel Millin; Katherine L Possin; Marzieh Nezamzadeh; Michael W Weiner; William J Marks; Norbert Schuff
Journal:  Mov Disord       Date:  2011-08-17       Impact factor: 10.338

6.  Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis.

Authors:  Wenbin Gu; Chen He; Juping Chen; Junchen Li
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

7.  Imaging improves diagnosis of dementia with lewy bodies.

Authors:  Masaru Tateno; Seiju Kobayashi; Toshikazu Saito
Journal:  Psychiatry Investig       Date:  2009-11-21       Impact factor: 2.505

8.  Case control study of diffusion tensor imaging in Parkinson's disease.

Authors:  L-L Chan; H Rumpel; K Yap; E Lee; H-V Loo; G-L Ho; S Fook-Chong; Y Yuen; E-K Tan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-07-05       Impact factor: 10.154

9.  Revolutionary impact of nanodrug delivery on neuroscience.

Authors:  Reza Khanbabaie; Mohsen Jahanshahi
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.